Compare Orion Office REIT Inc (ONL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs BIO-TECHNE Corp — how do they compare? Orion Office REIT Inc trades at $2.18 (market cap $125.50M), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 90.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.64%). Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and BIO-TECHNE Corp for 63 Days on average.
| ONL | TECH | |
|---|---|---|
Market Cap | $125.50M | $11.36B |
Volume | 303,276 | 5,390,331 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $72.61 |
52-Week Low | $1.93 | $43.31 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $542.43M | $11.39B |
Dividend Yield | 3.64% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.19, down 3.52% today, with a bearish technical signal despite a recent earnings beat. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Positive cash flow of $3.47M in 2025 and a low P/B of 0.2 offer value, but high debt and negative margins pose challenges. Analysts are split 50/50 between Buy and Hold.
Outlook remains cautious; deep discount to book value and strategic portfolio repositioning may attract value investors, but sustained losses and office sector headwinds limit near-term upside. Key risks include leverage pressure and execution of turnaround plans amid weak demand.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
